Synthesize Bio MCP

@synthesize-bio retrieve the latest sequencing results for project SYN-2024-03 and summarize quality metrics across all samples

Project SYN-2024-03 contains 12 samples with sequencing completed. Average read depth: 45x coverage. Quality scores: 8 samples exceed Q30 threshold (>90% bases), 3 samples show moderate quality (85-89%), 1 sample flagged for potential resequencing due to 78% Q30. Total data volume: 240GB across all runs. Most recent upload was 3 days ago.

This example assumes read-only access to sequencing data. Actual metrics depend on your lab's sequencing platform and quality thresholds. OAuth scope must include project data access. Response time varies with dataset size—large genomic files may take 10-15 seconds to process.

@synthesize-bio create a new plasmid design named pSYN-GFP-v2 with the standard backbone, GFP insert from our library, and ampicillin resistance marker

Created plasmid design pSYN-GFP-v2 (ID: PLS-8847). Components added: pUC19 backbone (2686 bp), eGFP coding sequence from library entry GFP-001 (720 bp), AmpR marker at standard position. Total construct size: 4,106 bp. Design saved to your workspace and marked as draft. No synthesis order placed—review the design in the Synthesize Bio interface before ordering.

This write operation creates a design record but does not trigger DNA synthesis or ordering. You'll need workspace write permissions. The MCP validates component compatibility but cannot catch all biological design issues—review restriction sites and expression context manually before synthesis.

@synthesize-bio compare expression levels between control and treatment groups in experiment EXP-445, then suggest which constructs should advance to the next validation round

Experiment EXP-445 shows 6 constructs with >2-fold expression increase over control (p<0.05). Top performers: pSYN-ENH-12 (3.8x, n=4 replicates), pSYN-ENH-07 (3.2x, n=4), pSYN-ENH-19 (2.4x, n=3). Recommend advancing these three plus pSYN-ENH-04 (2.1x but lowest variance). Constructs pSYN-ENH-02 and -15 showed no significant change. Two samples had insufficient data for statistical analysis.

This synthesis example combines experimental data retrieval with AI-driven analysis. The statistical thresholds and sample size requirements reflect typical molecular biology standards, but your lab may use different cutoffs. Always verify the underlying data—the AI's recommendations are starting points, not final decisions for wet-lab work.

When OAuth2 matters more than tool count for compliance teams

A three-person biotech startup writing an NIH grant needs to pull references from internal experiment logs and published papers without exposing API keys in shared prompts. Synthesize Bio MCP uses OAuth2, which means each team member authenticates once and the workspace inherits their scoped access—no rotating tokens, no accidental key leaks in chat history. This matters if you're handling pre-publication data or need audit trails for regulatory filings. The trade-off: OAuth2 setup takes 10 minutes per user, and if your team is just summarizing public PubMed abstracts, a simpler read-only MCP is faster to deploy. If your grant involves proprietary datasets or you need per-user attribution for compliance, the auth overhead pays off. Worth it for any biotech team writing grants or regulatory submissions where data provenance matters.

Placeholder MCP for teams waiting on tool documentation

A lab manager at a contract research org wants to query failed PCR runs and cross-reference vendor protocols during daily standups. Synthesize Bio MCP lists zero tools in the public registry, which means either the vendor hasn't documented them yet or the integration is in private beta. If you're evaluating this MCP today, ask the vendor for a tool manifest—specifically whether it can read experiment metadata, search protocol databases, or write back to a LIMS. Without that list, you're guessing whether it fits your workflow. The OAuth2 setup suggests it's built for secure data access, but until the tool count is public, treat this as a placeholder. If Synthesize Bio is your primary data platform and they've given you early access, test it in a single-use-case channel before rolling it out. Otherwise, wait for the tool list to ship.

When OAuth2 protects deal flow but tool gaps block execution

A two-person VC team tracking eight biotech investments needs to compare clinical trial progress across portfolio companies without mixing confidential data between deals. OAuth2 means each analyst authenticates to their own subset of companies, and Switchy enforces that boundary at the MCP layer—no risk of leaking Company A's trial data into a prompt about Company B. That's the right auth model for investor workflows. The problem: zero documented tools means you can't verify whether this MCP actually surfaces trial registries, patent filings, or FDA submissions. If Synthesize Bio has built those tools but hasn't published the list, request a private demo and test it in a single-deal channel. If the tools don't exist yet, this MCP is just secure plumbing with no faucet. Use it only if the vendor confirms your specific data sources are supported.